CVE-2019-15931

CVE-2019-15931 is a critical-severity vulnerability in Intesync Solismed with a CVSS 3.x base score of 9.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-22.

Key facts

Description

Intesync Solismed 3.3sp allows Directory Traversal, a different vulnerability than CVE-2019-16246.

Frequently asked questions

What is CVE-2019-15931?
Intesync Solismed 3.3sp allows Directory Traversal, a different vulnerability than CVE-2019-16246.
How severe is CVE-2019-15931?
CVE-2019-15931 has a CVSS 3.x base score of 9.8, rated critical severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2019-15931 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 3% (84th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2019-15931?
CVE-2019-15931 affects Intesync Solismed. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2019-15931?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its critical severity, prioritise patching exposed systems.
When was CVE-2019-15931 published?
CVE-2019-15931 was published on 2019-12-12 and last updated on 2026-06-17.

References

Affected products (1)

More vulnerabilities in Intesync Solismed

All CVEs affecting Intesync Solismed →

Other CWE-22 (Path Traversal) vulnerabilities

Browse all CWE-22 (Path Traversal) vulnerabilities →